FBLG

Fibrobiologics Inc

Add to Watchlist

Advanced Chart

0.649

+0.012(1.884%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.658

Open

0.637

VWAP

0.64

Vol

746.62K

Mkt Cap

23.99M

Low

0.6031

Amount

475.72K

EV/EBITDA(TTM)

Total Shares

41.89M

21.55M

EV/OCF(TTM)

P/S(TTM)

FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

2 Analyst Rating

1133.43% Upside

Wall Street analysts forecast FBLG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBLG is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

1133.43% Upside

Current: 0.649

Low

4.00

Averages

8.00

High

12.00

1133.43% Upside

Current: 0.649

Low

4.00

Averages

8.00

High

12.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-04-09

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-04-09

Maintains

Strong Buy

Reason

FibroBiologics announced a significant advancement in neurodegenerative disease research. Leveraging the Cuprizone animal model, FibroBiologics has demonstrated that intravenous fibroblasts can facilitate remyelination. FibroBiologics' Cuprizone animal model study demonstrated a statistically significant increase in myelin expression within seven weeks after both single and multiple dose fibroblast treatments. This confirms FibroBiologics' previous report of remyelination with the Experimental Autoimmune Encephalomyelitis animal model. "This confirmation by our talented team of researchers demonstrates that fibroblasts can support the regeneration of myelin sheath, marking a potentially significant step in the utilization of a cell-based therapeutic in regenerative medicine," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-04-01

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-04-01

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$12

2025-04-01

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$12

2025-04-01

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-03-04

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-03-04

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$16

2025-02-27

Reason

D. Boral Capital

Jason Kolbert

Price Target

$16

2025-02-27

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$12

2025-02-13

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$12

2025-02-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Fibrobiologics Inc (FBLG.O) is -1.48, compared to its 5-year average forward P/E of -10.83. For a more detailed relative valuation and DCF analysis to assess Fibrobiologics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.83

Current PE

-1.48

Overvalued PE

-0.66

Undervalued PE

-20.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00